The global mycoplasma infections diagnostics market is consolidated to a large extent with the leading five vendors jointly accounting for 68.0 % of the global market in 2016, notes Transparency Market Research (TMR). The leading companies are Lonza Group, Agilent Technologies, Merck KGaA, F. Hoffmann-La Roche, and Thermo Fisher Scientific, Inc. The global landscape is also markedly competitive and top vendors are focusing on entering into mergers and acquisitions and making geographic expansion, in order to consolidate their positions. However, the growing number of mergers, acquisitions, and collaborations in the global market will bring down the degree of competition to some extent, as the shares will be spread across few prominent shares in the years to come. TMR observes that a number of players are engaged in accelerating the development of technologically-advanced diagnostic kits with enhanced efficacy. Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php? flag=B&rep_id=1677 The global mycoplasma diagnostics market is projected to rise at a strong CAGR of 10.6% in between the forecast period of 2016 and 2024. Rising at this pace, the global market will rise from a worth of US$602.0 million in 2016 to reach a worth US$1.35 billion by 2024 end. The key technologies used in the diagnosis of mycoplasma infections are polymerase chain reaction (PCR), immunoassay, microbial culture techniques, and DNA staining. Of all the key segments, PCR method dominated the market in 2016 and its demand is projected to rise substantially through 2024. The popularity is attributed to increasing incidence of hospital-acquired and healthcare-associated infections world over. Regionally, North America led the global market with its dominant share in 2016. The extensive uptake of diagnostics for mycoplasma pneumoniae infections is attributed to the large number of laboratories present across the region and the heightened awareness among patient populations. Request for Analysis of COVID-19 Impact on Mycoplasma Infections Diagnostics Market https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1677 High Morbidity and Mortality of Respiratory Tract Infections bolster Demand for Mycoplasma Infections Diagnostics The global market for mycoplasma infections diagnostics is driven primarily by the growing prevalence of respiratory tract infections that can lead to incidence of lung cancer, tuberculosis, and obstructive pulmonary diseases. In addition, the concomitant rise in the associated mortality in worldwide populations is bolstering the demand for mycoplasma diagnostics. The rising demand for laboratory investigation for the diagnosis of mycoplasma pneumoniae pathogens is propelling the growth of the market. The rapid rise in geriatric population, especially in developing and developed nations, who are increasingly prone to respiratory tract infections is a crucial factor catalyzing the growth of the market. The rising awareness of the multiple etiologies that mycoplasma infections harbors among worldwide communities has accentuated the need for direct pathogen detection. Furthermore, the rising healthcare infrastructure spending by public and private players in developed regions is likely to help in the rapid expansion of the global market.
Mycoplasma Diagnostics Industry Size Insights Shared in Detailed Report
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.